The economics of hepatitis C virus.
Hepatitis C virus is a disease of major public health significance throughout the world in terms of overall morbidity and mortality and in its economic consequences and demands on medical resources. The global economic burden of this disease has yet to be fully realized. In this article the authors discuss the economic burden of hepatitis C, the economics of therapy, and the economics of its prevention and screening.
Shah
Bhavesh B
BB
Division of Clinical Decision Making, Informatics, and Telemedicine, Tufts-New England Medical Center, Tufts University School of Medicine, 750 Washington Street #302, Boston, MA 02111, USA.
Wong
John B
JB
D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000254:growth & development*; D006526:Hepatitis C / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D008403:Mass Screening / Q000191:economics; D011092:Polyethylene Glycols / Q000191:economics / Q000627:therapeutic use; D011634:Public Health / Q000191:economics; D011994:Recombinant Proteins; D012254:Ribavirin / Q000191:economics / Q000627:therapeutic use
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a